RxDoctor Payments Data

Tamara Johnson, MD

Family Medicine · North Platte, NENPI 1992739890

Payments from drug & device makers

$407in general payments, 2019–2025

Across 26 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$138
  • Takeda Pharmaceuticals U.S.A., Inc.$52
  • Boston Scientific$47
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • Sunovion Pharmaceuticals Inc.$39
  • Alkermes, Inc.$26
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$36088%
  • Education$4712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$407 in reported general payments places this provider in the 45th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$30,018
Medicare patients
97
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole101$283,556
VraylarCariprazine Hcl178$237,128
Invega SustennaPaliperidone Palmitate76$186,312
Risperdal ConstaRisperidone Microspheres46$112,090
IngrezzaValbenazine Tosylate12$96,864
AustedoDeutetrabenazine11$89,728
AristadaAripiprazole Lauroxil17$51,673
Lurasidone Hcl107$44,457
VyvanseLisdexamfetamine Dimesylate111$40,346
CaplytaLumateperone Tosylate20$33,074
BelsomraSuvorexant59$26,531
FanaptIloperidone13$24,012
LybalviOlanzapine/Samidorphan Malate12$19,624
LamictalLamotrigine24$16,382
TrintellixVortioxetine Hydrobromide30$14,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$12$283,556101 claims
AbbVieVraylar$138$237,128178 claims
Neurocrine Biosciences, Inc.Ingrezza$11$96,86412 claims
Teva Pharmaceuticals USA, Inc.Austedo$12$89,72811 claims
Alkermes, Inc.Aristada, Lybalvi$26$71,29729 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$52$55,254141 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$47$33,07420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 981 family medicine providers in Nebraska.

Other family medicine in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →